Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the first subject has been successfully dosed in a phase 2 clinical trial of IBI362, a glucagon-like peptide 1 receptor and glucagon receptor dual agonist in China.
June 15, 2021
· 6 min read